Synergistic effects of epoxyazadiradione (EAD) and paclitaxel against triple-negative breast cancer cells.
Kunnathully Sudhan SijishaRajitha AnushaSulochana PriyaPublished in: Fundamental & clinical pharmacology (2024)
To conclude, EAD could be the drug of choice for combined treatment with paclitaxel in a chemotherapy regimen.